These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 35056345)

  • 1. De Novo Minimal Change Disease following Vaccination with the Pfizer/BioNTech SARS-CoV-2 Vaccine in a Living Kidney Donor.
    Marinaki S; Kolovou K; Liapis G; Skalioti C; Tsiakas S; Boletis I
    Medicina (Kaunas); 2021 Dec; 58(1):. PubMed ID: 35056345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A de novo case of minimal change disease following the first dose of the Moderna mRNA-1273 SARS-CoV-2 vaccine without relapse after the second dose.
    Mochizuki RI; Takahashi N; Ikenouchi K; Shoda W; Kuyama T; Takahashi D
    CEN Case Rep; 2022 Nov; 11(4):477-481. PubMed ID: 35435622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New-onset pediatric nephrotic syndrome following Pfizer-BioNTech SARS-CoV-2 vaccination: a case report and literature review.
    Nakazawa E; Uchimura T; Hirai Y; Togashi H; Oyama Y; Inaba A; Shiga K; Ito S
    CEN Case Rep; 2022 May; 11(2):242-246. PubMed ID: 34782983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Minimal Change Disease Following the Pfizer-BioNTech COVID-19 Vaccine.
    Lebedev L; Sapojnikov M; Wechsler A; Varadi-Levi R; Zamir D; Tobar A; Levin-Iaina N; Fytlovich S; Yagil Y
    Am J Kidney Dis; 2021 Jul; 78(1):142-145. PubMed ID: 33839200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pediatric Minimal Change Disease and AKI following the Pfizer-BioNTech COVID-19 Vaccine: causal or incidental correlation?
    Annicchiarico Petruzzelli L; Minale B; Serio V; De Luca A; Marino Marsilia G; Campione S; Diomedi Camassei F; D'Arcangelo R; Luongo I; Lepore L; Giannattasio P; Molino D; Pirro L; Lonardo MC; Malgieri G; Pecoraro C
    G Ital Nefrol; 2022 Dec; 39(6):. PubMed ID: 36655832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nephrotic syndrome with minimal change disease after the Pfizer-BioNTech COVID-19 vaccine: two cases.
    Hartley JL; Bailey N; Sharma A; Shawki H
    BMJ Case Rep; 2022 Mar; 15(3):. PubMed ID: 35246429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Humoral immunity against SARS-CoV-2 in workers of social health care centers of Castilla y León after vaccination with the BNT162b2 mRNA vaccine from Pfizer/Biontech.].
    Casas Fischer R
    Rev Esp Salud Publica; 2021 Oct; 95():. PubMed ID: 34690347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exacerbation of Minimal Change Disease Following mRNA COVID-19 Vaccination.
    Pirzadeh A; Emami S; Zuckerman JE; Nobakht N
    Am J Case Rep; 2023 Nov; 24():e941621. PubMed ID: 37941318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autoimmune Hepatitis Following Vaccination for SARS-CoV-2 in Korea: Coincidence or Autoimmunity?
    Kang SH; Kim MY; Cho MY; Baik SK
    J Korean Med Sci; 2022 Apr; 37(15):e116. PubMed ID: 35437965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in IgG Antibody Responses following BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines.
    Montoya JG; Adams AE; Bonetti V; Deng S; Link NA; Pertsch S; Olson K; Li M; Dillon EC; Frosch DL
    Microbiol Spectr; 2021 Dec; 9(3):e0116221. PubMed ID: 34756093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relapse of minimal change disease following the third mRNA COVID-19 vaccination: a case report and literature review.
    Teragaki M; Tanaka M; Yamamoto H; Watanabe T; Takeoka J; Fukumi A; Maeda K; Takami Y; Saita H; Iwanari S; Ikeda M; Takeoka H
    CEN Case Rep; 2024 Feb; 13(1):53-58. PubMed ID: 37244881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia.
    Meo SA; Fahad Al-Jassir F; Al-Qahtani S; Albarrak R; Usmani AM; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Nov; 25(22):7185-7191. PubMed ID: 34859883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A child with crescentic glomerulonephritis following SARS-CoV-2 mRNA (Pfizer-BioNTech) vaccination.
    Kim S; Jung J; Cho H; Lee J; Go H; Lee JH
    Pediatr Nephrol; 2023 Jan; 38(1):299-302. PubMed ID: 35854121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of Graves' Disease After SARS-CoV-2 mRNA Vaccination: A Case Report and Literature Review.
    Lui DTW; Lee KK; Lee CH; Lee ACH; Hung IFN; Tan KCB
    Front Public Health; 2021; 9():778964. PubMed ID: 34888290
    [No Abstract]   [Full Text] [Related]  

  • 15. Evaluation of hematological parameters and thrombocytopenia following Pfizer-BioNTech (BNT162b2) SARS-CoV-2 vaccination.
    Algaissi A; Alamer E; Jeraiby M; Alomaish A; Elrhima O; Qumayi S; Qasir NA; Areeshi H; Masmali A; Alhazmi A
    Saudi Med J; 2022 Jun; 43(6):567-571. PubMed ID: 35675927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Humoral immune response after different SARS-CoV-2 vaccination regimens.
    Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
    BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Minimal change disease following the Moderna COVID-19 vaccine: first case report.
    Thappy S; Thalappil SR; Abbarh S; Al-Mashdali A; Akhtar M; Alkadi MM
    BMC Nephrol; 2021 Nov; 22(1):376. PubMed ID: 34763669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of mRNA-1273 and BNT162b2 SARS-CoV-2 mRNA Vaccine Immunogenicity in Kidney Transplant Recipients.
    Haller MC; Kaiser RA; Langthaler S; Brandstetter C; Apfalter P; Kerschner H; Cejka D
    Transpl Int; 2021; 35():10026. PubMed ID: 35185359
    [No Abstract]   [Full Text] [Related]  

  • 19. Status migrainosus: a potential adverse reaction to Comirnaty (BNT162b2, BioNtech/Pfizer) COVID-19 vaccine-a case report.
    Consoli S; Dono F; Evangelista G; D'Apolito M; Travaglini D; Onofrj M; Bonanni L
    Neurol Sci; 2022 Feb; 43(2):767-770. PubMed ID: 34807361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minimal Change Disease With Severe Acute Kidney Injury Following the Oxford-AstraZeneca COVID-19 Vaccine: A Case Report.
    Leclerc S; Royal V; Lamarche C; Laurin LP
    Am J Kidney Dis; 2021 Oct; 78(4):607-610. PubMed ID: 34242687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.